Rice Hall James & Associates LLC Makes New Investment in Prestige Consumer Healthcare Inc. $PBH

Rice Hall James & Associates LLC bought a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 689,692 shares of the company’s stock, valued at approximately $32,602,000. Prestige Consumer Healthcare comprises 1.6% of Rice Hall James & Associates LLC’s holdings, making the stock its 12th largest holding.

Several other hedge funds and other institutional investors have also recently modified their holdings of PBH. Dimensional Fund Advisors LP grew its holdings in shares of Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock worth $158,414,000 after acquiring an additional 91,710 shares during the period. State Street Corp increased its position in Prestige Consumer Healthcare by 1.4% during the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after acquiring an additional 27,721 shares during the last quarter. Morgan Stanley lifted its holdings in Prestige Consumer Healthcare by 6.3% in the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after acquiring an additional 71,078 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after acquiring an additional 35,126 shares during the period. Finally, Bank of America Corp DE boosted its position in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock worth $57,601,000 after purchasing an additional 115,459 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $49.93 on Tuesday. The company has a market capitalization of $2.37 billion, a PE ratio of 13.99, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The business’s fifty day moving average is $49.50 and its 200 day moving average is $55.41. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same quarter in the prior year, the business posted $0.90 earnings per share. The business’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).